Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma

Autor:	Brian T. Hill, Ronald Sobecks, Steven Andresen, Brian J. Bolwell, Brad Pohlman, John Sweetenham, Matt Kalaycio, Edward A. Copelan, Stephen D. Smith, Robert M. Dean, Lisa Rybicki, Shawnda Tench
Rok vydání:	2011
Předmět:	Adult Male Oncology Cancer Research medicine.medical_specialty Vincristine Time Factors Cyclophosphamide Hyper-CVAD Antigens CD34 Lymphoma Mantle-Cell Pharmacology Transplantation Autologous Dexamethasone Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Leukapheresis Hematopoietic Stem Cell Mobilization Aged Etoposide Retrospective Studies Peripheral Blood Stem Cell Transplantation business.industry Cytarabine Hematology Middle Aged Hematopoietic Stem Cells medicine.disease Chemotherapy regimen Methotrexate Treatment Outcome Doxorubicin Female Mantle cell lymphoma Stem cell business medicine.drug
Zdroj:	Leukemia & Lymphoma. 52:986-993
ISSN:	1029-2403 1042-8194
Popis:	Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate) is an intense chemotherapy regimen frequently used for hematologic malignancies including mantle cell lymphoma. To address whether treatment with hyper-CVAD impairs mobilization of peripheral blood stem cells, we retrospectively analyzed mobilization data from 77 consecutive adult patients with mantle cell lymphoma who underwent peripheral blood stem cell (PBSC) mobilization for planned autologous stem cell transplant (ASCT). Compared to patients treated with alternative regimens, patients treated with hyper-CVAD collected fewer CD34+ cells, required more total days of pheresis, and more frequently required a second mobilization attempt, despite being more likely to have undergone mobilization with a VP16-containing regimen. In multivariable linear regression analysis, treatment with hyper-CVAD was associated with a significant reduction in total CD34+ cells mobilized (p 0.001). These findings suggest that alternative mobilizing strategies prior to ASCT are needed for patients with mantle cell lymphoma who have received hyper-CVAD.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::391c43db7416efd09e2c4949f718bd2f https://doi.org/10.3109/10428194.2010.551154 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.